Co-treatment with KPA also decreased the expression of genes (Figure 7I,J), regulating the progression of fibrosis (e.g., COL6A3, AEBP1, SPARC, TNC, LAMB1, BGN) and hepatocellular carcinoma (e.g., COL4A1, COL4A2, TUFT1, VCAN, NID1). The gene discussed is COL4A2; the disease is hepatocellular carcinoma.